Global Respules Market - 2023-2030

Global Respules Market - 2023-2030

The Global Respules Market size reached US$ 1.5 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 2.5 billion by 2030. The market is expected to exhibit a CAGR of 6.1% during the forecast period 2023-2030.

Respules are often used to provide medicine to patients suffering from respiratory illnesses such as asthma, chronic obstructive pulmonary disease (COPD) and other lung ailments. Bronchodilators, corticosteroids and other medications that assist to open up the airways, reduce inflammation, and enhance breathing may be included within the respule.

To use a respule, the patient normally connects it to the nebulizer and then inhales the nebulizer mist through a mouthpiece or mask. The thin mist permits the drug to penetrate deep into the lungs, where it may be efficiently absorbed.

Market Dynamics

Growing Prominence of Home Healthcare

Growing prominence of home helathcare is the key driver that drives respules market during the forecast period.Home-use, portable nebulizers have become one of the fundamentals aiding patients at home as home healthcare crafts its own position in the global healthcare industry. In recent years, there has been a marked increase in the choice for home treatment over costly hospitalisations.

Portable, small nebulizers are widely available on the market and are marketed as the most convenient tool for patients to use at home. Frequent category developments aimed at improving functionality are likely to boost the rate of adoption in the worldwide nebulizer market.

Increasing Number Of Launches in Generic Version Of Budesonide Inhaler

The increasing number of generic budesonide inhaler releases is a crucial driver for the market to develop throughout the projected period. Budesonide can significantly improve symptoms in persons with inflammatory bowel disease. In those with active illness, it may also promote remission.

For instance,On march 15 2022 the Food and Drug Administration (FDA) recently approved a generic Symbicort (budesonide and formoterol fumarate dihydrate) metered-dose inhaler for the treatment of asthma or chronic obstructive pulmonary disease (COPD).

Risk of Disease Transmission & Availability Of Alternate Treatment Options

Concerns have been raised about the safety profile of breathing devices in terms of infection transfer. Factors such as the possibility of infection transfer from nebulizer tubing to the patient's lungs or infection transmission from the devices' unsterile chambers restrict healthcare providers' recommendations for the usage of these devices.

For instance According to article published on March 2020 in the Canadian Medical Association Journal, the risk of infection transmission increased during nebulizer treatments due to their ability to generate a high volume of respiratory aerosols, which increases the risk of disease spread. As a result of these considerations, several centres have moved from utilising nebulizers to metered dosage inhalers in recent years.

COVID-19 Impact Analysis

During the first wave of COVID-19 in the UK, there was a significant increase in prescriptions for asthma inhalers, with manufacturers reporting that certain inhalers were out of stock and the Department of Health and Social Care issuing a statement urging practitioners not to overprescribe inhalers.

During the same time period, there was a considerable decrease in the number of asthma exacerbations handled in primary care, with one possible explanation being better adherence to asthma medication. Other explanations include decreased virus exposure and apprehension about presenting to healthcare services.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict had a influence on the global respules market due to its low prevalence and lack of important industry participants. Factors such as supply chain interruption, damage to healthcare infrastructure and access to electricity utilities have all contributed to the rise of repulse makret.

Segment Analysis

The global Respules market is segmented based on drug type, dosage & strength, distribution channel and region.

The Budesonide Drug Type Segment is Estimated To Hold A Majority Of The Respules Market Share During The Forecast Period.

The Budesonide Drug type holds about 39.1% of the total respules market in the forecast period.Budesonide is a glucocorticosteroid that has a dose-dependent anti-inflammatory activity in the airways when breathed. Budesonide inhalation has fewer severe side effects than systemic corticosteroids. Although the specific mechanism responsible for budesonide's anti-inflammatory activity is unknown, it has been found to be particularly efficient against the typical inflammation of asthma.

For instance The UK's first dual combination inhaler for moderate asthma has been approved by the medicines regulator. The UK's first dual combination relief inhaler for moderate asthma has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA).

According to a statement released by AstraZeneca on March 23, 2023, the inhaler might be used by approximately 2.7 million adults in the UK who live with mild asthma.

Budesonide/formoterol 200/6 is the first and only dual combination medication licenced in the UK for mild asthma, where there is a significant unmet clinical need,"" according to the statement, adding that the approval was based on data from clinical studies involving over 9,500 patients.

Geographical Analysis

North America is Estimated to Hold the Largest Share of the Global Respules Market During the Forecast Period.

The North America region holds the second largest share of the global Respules market accounting for approximately 41.4% in the forecast period.

For instance The rising frequency of respiratory diseases, as well as FDA approvals, are likely to drive market expansion in this area.For instance, According to the CDC, 42.7% of children aged 18 and under who had asthma had one or more asthma episodes in the previous year in 2021.A total of 52.9% of children under the age of five who had asthma experienced an episode.

Despite the fact that asthma is treatable, it is believed that half of all children with asthma have uncontrolled asthma. In 2020, 40.7% of individuals aged 18 and up with asthma reported one or more asthma episodes in the previous year.

Competitive Landscape

The major global players in the market include Cipla, AstraZeneca, Sandoz International, Bio chemix Healthcare, Lupin, Amanta Healthcare, Lxir Medilabs, Intra Life, Cosmo Pharmaceuticals and Lunan Better Pharmaceutical.

Why Purchase the Report?
• To visualize the global respules market segmentation based on type, distribution channel, and region,as well as understandkey commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of respules market-level with all segments.
• PDF report consists of a comprehensiveanalysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Respules Market Report Would Provide Approximately 53 Tables, 54 Figures and 195 Pages.

Target Audience 2023
• Manufacturers / Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies